Drug Shortage Report for ERAXIS
Report ID | 136227 |
Drug Identification Number | 02330695 |
Brand name | ERAXIS |
Common or Proper name | ERAXIS |
Company Name | PFIZER CANADA ULC |
Market Status | MARKETED |
Active Ingredient(s) | ANIDULAFUNGIN |
Strength(s) | 100MG |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 30mL vial |
ATC code | J02AX |
ATC description | ANTIMYCOTICS FOR SYSTEMIC USE |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-04-01 |
Estimated end date | |
Actual end date | 2021-05-12 |
Shortage status | Resolved |
Updated date | 2021-05-13 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v10 | 2021-05-13 | English | Compare |
v9 | 2021-05-12 | French | Compare |
v8 | 2021-05-12 | English | Compare |
v7 | 2021-04-05 | French | Compare |
v6 | 2021-04-05 | English | Compare |
v5 | 2021-04-02 | English | Compare |
v4 | 2021-03-31 | French | Compare |
v3 | 2021-03-31 | English | Compare |
v2 | 2021-03-25 | French | Compare |
v1 | 2021-03-25 | English | Compare |
Showing 1 to 10 of 10